瑞舒伐他汀对冠心病PCI术后心绞痛的临床疗效  

Clinical Efficacy of Rosuvastatin on Angina Pectoris after PCI in Patients with Coronary Heart Disease

作　　者：赖绍斌 庾海清[1] 石镇涛 杨春万[1] 张小乐[1] 桑喜梅[1] LAI Shaobin;YU Haiqing;SHI Zhentao(Zhaoqing First People’s Hospital,Zhaoqing 526040,Chin)

机构地区：[1]广东省肇庆市第一人民医院,广东肇庆526040

出　　处：《中国医学创新》2018年第20期11-15,共5页Medical Innovation of China

基　　金：广东省肇庆市科技局项目(A2017519)

摘　　要：目的:分析冠心病(CHD)PCI术后心绞痛患者采用瑞舒伐他汀治疗的临床效果。方法:选取2015年1月-2018年1月于本院收治的冠心病PCI术后心绞痛患者610例为研究对象,依据不同的治疗方式将其分为对照组和观察组,每组305例。两组均接受常规治疗,在此基础上,于术前7 d对照组采用阿托伐他汀钙片进行治疗,观察组采用瑞舒伐他汀进行治疗,对比两组治疗前后血脂、炎性因子、心肌损伤指标、血管内皮功能指标水平变化,以及心绞痛发作情况。结果:治疗后,观察组各项血脂指标水平均优于对照组,差异均有统计学意义(P<0.05)。与治疗前对比,观察组治疗后INF-γ、INF-α、hs-CRP水平均有所提高,差异均有统计学意义(P<0.05);而IL-10、IL-6提高幅度不大,差异均无统计学意义(P>0.05)。治疗后,对照组各项炎性因子指标水平均显著提高,且均高于观察组,差异均有统计学意义(P<0.05)。观察组治疗后的N0水平高于对照组,ET-1水平低于对照组,差异均有统计学意义(t=12.678 2、18.732 1,P=0.000 0、0.000 0)。结论:冠心病PCI术后心绞痛患者采用瑞舒伐他汀治疗的临床效果显著,能有效改善患者的炎性因子水平、血管内皮功能与血脂水平,值得推广。Objective：To analyze the clinical effect of Rosuvastatin on angina pectoris after PCI in patients with coronary heart disease（CHD）.Method：A total of 610 patients with angina pectoris after PCI coronary heart disease who were treated in our hospital from January 2015 to January 2018 were selected as the study objects.According to the different treatment methods,they were divided into control group and observation group,305 cases in each group.Both groups were received conventional treatment,the control group was treated with Atorvastatin Calcium Tablets before surgery 7 d on basis of this,the observation group was treated with Rosuvastatin.The changes of blood lipids,inflammatory factors,myocardial damage markers,vascular endothelium function and angina pectoris between the two groups were compared before and after treatment.Result：After treatment,the blood lipid levels in the observation group were better than those in the control group,the differences were statistically significant（P〈0.05）.Compared with before treatment,the levels of INF-γ,INF-α and hs-CRP in the observation group were increased after treatment,the differences were statistically significant（P〈0.05）,while the increase of IL-10 and IL-6 were not significant（P〈0.05）.After treatment,the levels of inflammatory factors in the control group were significantly increased and higher than those in the observation group,the differences were statistically significant（P〈0.05）.After treatment,the level of NO in the observation group was significantly higher than that in the control group,and the level of ET-1 was significantly lower than that in the control group,the differences were statistically significant（t=12.678 2,18.732 1;P=0.000 0,0.000 0）. Conclusion：The clinical effect of Rosuvastatin in the treatment of coronary heart disease after PCI patients with angina pectoris is significant,it can effectively improve the level of inflammatory factors, vascular endothelial function and blood lipids in patients with coro

关 键 词：冠心病 PCI术 心绞痛 瑞舒伐他汀 

分 类 号：R541.4[医药卫生—心血管疾病]